<?xml version="1.0" encoding="utf-8" standalone="no"?>
<billStatus>
  <version>3.0.0</version>
  <bill>
    <number>5927</number>
    <updateDate>2022-02-09T01:42:21Z</updateDate>
    <updateDateIncludingText>2022-02-09T01:42:21Z</updateDateIncludingText>
    <originChamber>House</originChamber>
    <type>HR</type>
    <introducedDate>2020-02-18</introducedDate>
    <congress>116</congress>
    <constitutionalAuthorityStatementText><![CDATA[<pre>[Congressional Record Volume 166, Number 33 (Tuesday, February 18, 2020)][House]From the Congressional Record Online through the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]By Mr. POSEY:H.R. 5927.Congress has the power to enact this legislation pursuantto the following:Article 1 Section 8 of the Constitution declares thatCongress has the power ``To regulate commerce with foreignnations, and among the several states, and with the Indiantribes;'' Article 2 Section 2 allows Congress to create otherexecutive officers. Finally, in Article 1, Section 8clarifies that Congress has the right to make ``all Lawswhich shall be necessary and proper for carrying intoExecution the foregoing Powers.''It is in keeping with the power invested in Congress underthese articles to direct the Secretary of Health and HumanServices (HHS) to study our dependence on Chinesepharmaceuticals; direct HHS to provide recommendations forweaning the American people off this dangerous dependence;and authorize the U.S. Food and Drug Administration to issueblack-box warnings informing consumers of any risk they aretaking when using pharmaceuticals from countries withsystemic issues of supervision.[Page H1164]</pre>]]></constitutionalAuthorityStatementText>
    <committees>
      <item>
        <systemCode>hsif00</systemCode>
        <name>Energy and Commerce Committee</name>
        <chamber>House</chamber>
        <type>Standing</type>
        <activities>
          <item>
            <name>Referred to</name>
            <date>2020-02-18T15:30:15Z</date>
          </item>
        </activities>
      </item>
    </committees>
    <relatedBills>
      <item>
        <title>Safe Medicine Act</title>
        <congress>116</congress>
        <number>5982</number>
        <type>HR</type>
        <latestAction>
          <actionDate>2020-02-26</actionDate>
          <text>Referred to the House Committee on Energy and Commerce.</text>
        </latestAction>
        <relationshipDetails>
          <item>
            <type>Related bill</type>
            <identifiedBy>CRS</identifiedBy>
          </item>
        </relationshipDetails>
      </item>
    </relatedBills>
    <actions>
      <item>
        <actionDate>2020-02-18</actionDate>
        <text>Referred to the House Committee on Energy and Commerce.</text>
        <type>IntroReferral</type>
        <actionCode>H11100</actionCode>
        <sourceSystem>
          <code>2</code>
          <name>House floor actions</name>
        </sourceSystem>
        <committees>
          <item>
            <systemCode>hsif00</systemCode>
            <name>Energy and Commerce Committee</name>
          </item>
        </committees>
      </item>
      <item>
        <actionDate>2020-02-18</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>Intro-H</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
      <item>
        <actionDate>2020-02-18</actionDate>
        <text>Introduced in House</text>
        <type>IntroReferral</type>
        <actionCode>1000</actionCode>
        <sourceSystem>
          <code>9</code>
          <name>Library of Congress</name>
        </sourceSystem>
      </item>
    </actions>
    <sponsors>
      <item>
        <bioguideId>P000599</bioguideId>
        <fullName>Rep. Posey, Bill [R-FL-8]</fullName>
        <firstName>Bill</firstName>
        <lastName>Posey</lastName>
        <party>R</party>
        <state>FL</state>
        <district>8</district>
        <isByRequest>N</isByRequest>
      </item>
    </sponsors>
    <policyArea>
      <name>Health</name>
    </policyArea>
    <subjects>
      <legislativeSubjects>
        <item>
          <name>Administrative law and regulatory procedures</name>
        </item>
        <item>
          <name>Asia</name>
        </item>
        <item>
          <name>China</name>
        </item>
        <item>
          <name>Congressional oversight</name>
        </item>
        <item>
          <name>Drug safety, medical device, and laboratory regulation</name>
        </item>
        <item>
          <name>Government studies and investigations</name>
        </item>
        <item>
          <name>Health care costs and insurance</name>
        </item>
        <item>
          <name>Health information and medical records</name>
        </item>
        <item>
          <name>Health technology, devices, supplies</name>
        </item>
        <item>
          <name>Manufacturing</name>
        </item>
        <item>
          <name>Prescription drugs</name>
        </item>
        <item>
          <name>Public contracts and procurement</name>
        </item>
        <item>
          <name>Trade restrictions</name>
        </item>
      </legislativeSubjects>
      <policyArea>
        <name>Health</name>
      </policyArea>
    </subjects>
    <summaries>
      <summary>
        <versionCode>00</versionCode>
        <actionDate>2020-02-18</actionDate>
        <actionDesc>Introduced in House</actionDesc>
        <updateDate>2021-09-07T20:22:15Z</updateDate>
        <text><![CDATA[ <p><strong>Safe Medicine Act</strong></p> <p>This bill authorizes the Food and Drug Administration to temporarily ban the sale of a drug if (1) the drug (or an active ingredient of the drug) is manufactured in a country that, because of systemic problems of supervision, may be producing contaminated drugs; and (2) the drug's labeling does not have certain warnings about potential contamination. </p> <p>The bill also requires the Department of Health and Human Services to report to Congress on vulnerabilities in the U.S. medicine supply chain, including vulnerabilities related to reliance on production from other countries.</p>]]></text>
      </summary>
    </summaries>
    <title>Safe Medicine Act</title>
    <titles>
      <item>
        <titleType>Display Title</titleType>
        <title>Safe Medicine Act</title>
      </item>
      <item>
        <titleType>Official Title as Introduced</titleType>
        <title>To direct the Secretary of Health and Human Services to study American dependence on unsafe Chinese pharmaceuticals and to empower the Food and Drug Administration to mandate drug recalls in the case of critical contamination.</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
      <item>
        <titleType>Short Title(s) as Introduced</titleType>
        <title>Safe Medicine Act</title>
        <billTextVersionName>Introduced in House</billTextVersionName>
        <billTextVersionCode>IH</billTextVersionCode>
      </item>
    </titles>
    <textVersions>
      <item>
        <type>Introduced in House</type>
        <date>2020-02-18T05:00:00Z</date>
        <formats>
          <item>
            <url>https://www.govinfo.gov/content/pkg/BILLS-116hr5927ih/xml/BILLS-116hr5927ih.xml</url>
          </item>
        </formats>
      </item>
    </textVersions>
    <latestAction>
      <actionDate>2020-02-18</actionDate>
      <text>Referred to the House Committee on Energy and Commerce.</text>
    </latestAction>
  </bill>
  <dublinCore xmlns:dc="http://purl.org/dc/elements/1.1/">
    <dc:format>text/xml</dc:format>
    <dc:language>EN</dc:language>
    <dc:rights>Pursuant to Title 17 Section 105 of the United States Code, this file is not subject to copyright protection and is in the public domain.</dc:rights>
    <dc:contributor>Congressional Research Service, Library of Congress</dc:contributor>
    <dc:description>This file contains bill summaries and statuses for federal legislation. A bill summary describes the most significant provisions of a piece of legislation and details the effects the legislative text may have on current law and federal programs. Bill summaries are authored by the Congressional Research Service (CRS) of the Library of Congress. As stated in Public Law 91-510 (2 USC 166 (d)(6)), one of the duties of CRS is "to prepare summaries and digests of bills and resolutions of a public general nature introduced in the Senate or House of Representatives". For more information, refer to the User Guide that accompanies this file.</dc:description>
  </dublinCore>
</billStatus>
